Dragonfly Therapeutics to Present Phase 1 DF1001 Monotherapy Dose Escalation Results at ASCO 2023 Annual Meeting

"We look forward to presenting our DF1001 Phase 1 study results at ASCO," said Joseph Eid, MD, President of Research and Development at Dragonfly Therapeutics. DF1001 is a first-in-class immune modulating TriNKET targeting HER2 that drives immune activation in solid tumors. DF1001 is also being evaluated in combination with nivolumab or nab paclitaxel. Clinical trial sites are open in the U.S., France, Belgium, Denmark and The Netherlands. Additional information about the trial, including eligibility criteria, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04143711).

"We look forward to presenting our DF1001 Phase 1 study results at ASCO," said Joseph Eid, MD, President of Research and Development at Dragonfly Therapeutics. DF1001 is a first-in-class immune modulating TriNKET targeting HER2 that drives immune activation in solid tumors. DF1001 is also being evaluated in combination with nivolumab or nab paclitaxel. Clinical trial sites are open in the U.S., France, Belgium, Denmark and The Netherlands. Additional information about the trial, including eligibility criteria, can be found at: https://clinicaltrials.gov (ClinicalTrials.gov Identifier: NCT04143711).

About DF1001
DF1001 is an investigational first-in-class drug candidate that targets natural killer (NK) cells and T-cell activation signals to co-activating NK receptors, where NKG2D and CD16 co-stimulation yields distinctive and potent NK cell activation. DF1001 is being evaluated in adult patients for the treatment of advanced solid HER2-positive tumors. DF1001 was discovered and developed using Dragonfly's TriNKET Platform. DF1001 has the potential to stimulate effective anti-tumor immunity in patients who are not eligible or not adequately responding to current therapies. DF1001 is the most advanced in a pipeline of TriNKETs that Dragonfly is developing to address high unmet needs for patients across a broad range of disease areas.

About Dragonfly
Dragonfly Therapeutics is a clinical-stage biopharmaceutical company committed to discovering, developing, and commercializing therapies that use its novel bispecific antibody technology to harness the body's immune system to bring breakthrough treatments to patients. In addition to its wholly-owned clinical assets and multiple assets in the clinic with partners, Dragonfly has a deep pipeline of wholly-owned preclinical candidates developed using its proprietary platforms as well as productive collaborations with Merck, AbbVie, Gilead and Bristol Myers Squibb, in a broad range of disease areas. 

For more information visit: 
www.dragonflytx.com
https://www.linkedin.com/company/dragonfly-therapeutics-inc./
https://twitter.com/dragonflytx 

DRAGONFLY MEDIA CONTACT:
Anne Deconinck | anne@dragonflytx.com 

Logo - https://mma.prnewswire.com/media/390962/4066598/Dragonfly_Therapeutics_Inc_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/dragonfly-therapeutics-to-present-phase-1-df1001-monotherapy-dose-escalation-results-at-asco-2023-annual-meeting-301840938.html